The U.S. House Appropriations Committee says HRSA should use "any available means" to hold drug makers accountable for curtailing "use of 340B drugs in contract pharmacies."
House Appropriators Ask Feds to Use “Any Available Measures” to Curb Pharma’s 340B Pricing Denials
The U.S. House Appropriations Committee said this week it is concerned about the growing number of drug manufacturers “that curtail the use of 340B drugs in contract pharmacies.” It encouraged the U.S. Health Resources and Services Administration to use “any available measures,” including imposing civil monetary penalties, “to hold those drug manufacturers in violation of the law directly accountable.”
The committee is marking up its fiscal year 2023 spending bill for labor, healthcare, and related agencies today. It released its report to accompany the bill yesterday. Appropriations bills traditionally start in the House. It has passed none of the 12 bills for fiscal 2023 yet. Because this is an election year, there are fewer congressional workdays in Washington scheduled so members can campaign. Funding for all or most government agencies probably will be provided for under a series of temporary catch-all spending bills.
The U.S. House Appropriations Committee said this week it is concerned about the growing number of drug manufacturers “that curtail the use of 340B drugs in contract pharmacies.”